While some studies have found that appropriately reducing basal and mealtime insulin doses in T2DKD patients undergoing multiple daily injection (MDI) therapy can decrease the incidence of hypoglycemia without affecting glycemic control, there are currently no reports on the insulin dose characteristics used in CSII therapy for T2DKD patients. The gene discussed is INS; the disease is Hypoglycemia.